Beta
412070

Evaluation of the Antifungal Effect of Fluconazole and Ivermectin against Candida albicans

Article

Last updated: 25 Feb 2025

Subjects

-

Tags

Antimicrobial agents

Abstract

Background: Ivermectin is (macrocyclic lactones) which are products or chemical derivatives of soil microorganisms belonging to the fungus Streptomyces avermitilis. Objective: The aim of the study is to evaluate the antifungal efficacy of Fluconazole and Ivermectin individually and in combination against Fluconazole-resistant Candida albicans isolates in vitro and in an in vivo rat model. Methodology: Twenty-five Fluconazole-resistant C. albicans isolates were tested for synergistic effects of Fluconazole and Ivermectin. Thirty-two male rats with/without infections will received treatments and fungal burden and survival was assessed. The antifungal efficacy was determined by measuring the zone of inhibition in a well diffusion experiment. Results: The MIC was 3.7 µg for Ivermectin and 11.1 µg for Fluconazole. Antifungal assay of Ivermectin alone (8µg) showed large inhibition zone (15.1 mm) compared to (3.7µg) showed inhibition zone (11.9 mm) and (1 µg) small inhibition zone (8.63mm). Antifungal assay of Ivermectin in combination with Fluconazole (8-11µg) show large inhibition zone (40 mm) compared to (3.7-11µg) less inhibition zone (25.9 mm) and last combination (1-11µg) show small inhibition zone (12.1mm). Animal study of Ivermectin shows the best combination with Fluconazole which showed faster healing time and reduce size of infection from (2-0.2cm) and disappeared redness of skin and return growth of hair is (8-11 µg) of Ivermectin. Conclusion: Ivermectin showed potent antifungal activity against Fluconazole-resistant C. albicans with MICs ranging from 3.7-100µg/ml. Combining Ivermectin and Fluconazole demonstrated synergistic effects leading to faster treatment response and complete resolution of fungal infection within 21 days in the in vivo model.

DOI

10.21608/ejmm.2025.355623.1450

Keywords

C. albicans. Fluconazole. Ivermectin. synergistic effect

Authors

First Name

Ihssan

Last Name

Jubair

MiddleName

A.

Affiliation

Department of Clinical Laboratory Sciences College of Pharmacy, Basrah University, Basrah, Iraq

Email

ihssanalijubair@gmail.com

City

Basra

Orcid

-

First Name

Dawood

Last Name

Hilayail

MiddleName

C.

Affiliation

Department of Clinical Laboratory Sciences College of Pharmacy, Basrah University, Basrah, Iraq

Email

dawood.hilayil@uobasrah.edu.iq

City

Basra

Orcid

-

First Name

Jubran

Last Name

Hassan

MiddleName

K.

Affiliation

Department of Clinical Laboratory Sciences College of Pharmacy, Basrah University, Basrah, Iraq

Email

jubran.hassan@uobasrah.edu.iq

City

Basra

Orcid

-

Volume

34

Article Issue

3

Related Issue

53640

Issue Date

2025-07-01

Receive Date

2025-02-06

Publish Date

2025-07-01

Print ISSN

1110-2179

Online ISSN

2537-0979

Link

https://ejmm.journals.ekb.eg/article_412070.html

Detail API

http://journals.ekb.eg?_action=service&article_code=412070

Order

412,070

Type

New and original researches in the field of Microbiology.

Type Code

2,038

Publication Type

Journal

Publication Title

Egyptian Journal of Medical Microbiology

Publication Link

https://ejmm.journals.ekb.eg/

MainTitle

Evaluation of the Antifungal Effect of Fluconazole and Ivermectin against Candida albicans

Details

Type

Article

Created At

25 Feb 2025